SCHEMBL12377831

SCHEMBL12377831

Cc1cccc(-c2nn(CCN3CCCC3=O)c(=O)o2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 5/20 0.42
GRIN2B Q13224 5/20 0.42
NLRP3 Q96P20 1/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
NOTUM Q6P988 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12377829 0.78 GRIN1 (0.47) GRIN1GRIN2BNPC1RAB9ASMN1; SMN2
SCHEMBL12377825 0.78 GRIN1 (0.47) GRIN1GRIN2BNPC1RAB9ASMN1; SMN2
SCHEMBL12377822 0.77 IL2 (0.49) GRIN1GRIN2BNPC1RAB9ASMN1; SMN2
SCHEMBL12377828 0.76 GRIN1 (0.46) GRIN1GRIN2BNPC1RAB9ASMN1; SMN2
SCHEMBL12377824 0.74 NOTUM (0.47) GRIN1GRIN2BKMT2ANPC1RAB9A
SCHEMBL12377834 0.73 GRIN1 (0.43) GRIN1GRIN2BKMT2ANPC1RAB9A
SCHEMBL12377830 0.72 NOTUM (0.45) GRIN1GRIN2BNPC1RAB9ASMN1; SMN2
SCHEMBL12377833 0.72 GAA (0.47) GRIN1GRIN2BKMT2ANPC1RAB9A
SCHEMBL12377820 0.72 NOTUM (0.55) NPC1RAB9ASMN1; SMN2MAPTNOTUM
SCHEMBL9186057 0.71 NOTUM (0.43) GRIN1GRIN2BNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D GRIN1 245/4885GRIN2B 325/4885NLRP3 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.